Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 16/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489060 | 0.95 | PDK2 (0.38) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL12488738 | 0.90 | PDK2 (0.38) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL12488689 | 0.86 | MEN1 (0.33) | FASNPDK2PDK4 | |
| SCHEMBL28974042 | 0.85 | FASN (0.38) | FASN | |
| SCHEMBL12686837 | 0.84 | FASN (0.42) | FASNPDK2PDK4SLC6A3 | |
| Hydrochloric Acid SCHEMBL12489011 | 0.83 | FASN (0.41) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL12489091 | 0.82 | FASN (0.39) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL12488865 | 0.81 | FASN (0.51) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL18432288 | 0.81 | PDK2 (0.40) | FASNPDK2PDK4SLC6A3 | |
| SCHEMBL12488071 | 0.80 | CYP3A4 (0.39) | PDK2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055152-A | Combination therapy of FASN inhibitors with thyroid hormone receptor agonists | 萨吉米特生物科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4731212-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | Sagimet Biosciences Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260048061-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | SAGIMET BIOSCIENCES INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250017938-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | SAGIMET BIOSCIENCES INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2024263785-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | SAGIMET BIOSCIENCES INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2683244-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | FASN, FADS1, FADS2 | FASN 1/4885PDK2 281/4885PDK4 261/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885PDK2 243/4885PDK4 223/4885 |
| US-20260048061-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | THRB, THRA, TSHR | FASN 4/4885PDK2 2016/4885PDK4 853/4885 |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885PDK2 314/4885PDK4 271/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | FASN 1/4885PDK2 1856/4885PDK4 1237/4885 |
| US-20250017938-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | TSHR, FASN, THRA | FASN 2/4885PDK2 1623/4885PDK4 702/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | FASN 1/4885PDK2 233/4885PDK4 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.